Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Syngen Biotech CoROCO:8279 +1.03%89 EBITDA Margin % is 16.42% as of Dec. 2025, which is 31% below its 10-year median of 23.64. GuruFocus rates ROCO:8279 with a GF Score™ of 89/100 and a GF Value™ of NT$158.15 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 940 Biotechnology companies, Syngen Biotech Co ranks better than 84.15% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Syngen Biotech Co's EBITDA for the
three
months ended in Dec. 2025 was NT$79 Mil. Syngen Biotech Co's Revenue for the
three
months ended in Dec. 2025 was NT$480 Mil. Therefore, Syngen Biotech Co's EBITDA margin for the quarter that ended in Dec. 2025 was 16.42%.
Syngen Biotech Co (ROCO:8279) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Syngen Biotech Co EBITDA Margin % Related Terms
Syngen Biotech Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Syngen Biotech Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:8279 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Syngen Biotech Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syngen Biotech Co EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Syngen Biotech Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Syngen Biotech Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Syngen Biotech Co (ROCO:8279) has a EBITDA Margin % of 16.42% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Syngen Biotech Co and its competitors. This is 31% below median its historical median of 23.64. Over the past decade, Syngen Biotech Co's EBITDA Margin % has ranged from 19.08 to 26.12. According to the industry distribution chart, Syngen Biotech Co ranks #149 out of 940 companies in the Biotechnology industry, placing it in the top 15.9%.
Is Syngen Biotech Co's EBITDA Margin % too high?
Syngen Biotech Co's current EBITDA Margin % of 16.42% is 31% below median its 10-year median of 23.64. Over the past 10 years, this metric has ranged from a low of 19.08 to a high of 26.12. Based on the distribution chart, Syngen Biotech Co ranks #149 out of 940 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Syngen Biotech Co has a GF Score™ of 89/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Syngen Biotech Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Syngen Biotech Co ranks #149 out of 940 companies for EBITDA Margin %. This places Syngen Biotech Co in the top 16% of its industry — outperforming the majority of peers. Historically, Syngen Biotech Co's own EBITDA Margin % has ranged from 19.08 to 26.12 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Syngen Biotech Co and its competitors. Syngen Biotech Co's current EBITDA Margin % is 16.42%, which is 31% below median its own 10-year median of 23.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syngen Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Syngen Biotech Co (ROCO:8279) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$158.15, compared to a current price of NT$88.50 — trading 44% below its estimated fair value. The current EBITDA Margin % is 16.42%, which is 31% below median its 10-year median of 23.64. Syngen Biotech Co's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Syngen Biotech Co (ROCO:8279), the current EBITDA Margin % is 16.42% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Syngen Biotech Co (ROCO:8279) Overvalued in 2026?
Based on GuruFocus' analysis, Syngen Biotech Co stock appears to be undervalued.
The current stock price of NT$88.50 is trading 44% below its estimated GF Value™ of NT$158.15.
GuruFocus considers Syngen Biotech Co to be Significantly Undervalued.
Key valuation signals for ROCO:8279:
EBITDA Margin %: 16.42% (31% below median its 10-year median of 23.64)
GF Value™: NT$158.15 vs. price of NT$88.50 (44% below fair value)
No single metric tells the full story. See the ROCO:8279 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Syngen Biotech Co Ltd is a biotechnology company. It is engaged in the manufacturing, sales, and trading of microbial pharmaceutical raw materials. It also provides the design and development of health food and biochemical nutrition. The company's products include pharmaceutical ingredients, nutritional ingredients, biology fermentation products, biology agriculture and aquaculture products.
89GF Score
Get the complete analysis for ROCO:8279
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:8279 has been successfully added to your 
